Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 11/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1463268 | 1.00 | THRB (0.44) | THRBJAK1TYK2PDE2ANPC1 | |
| SCHEMBL1463010 | 1.00 | THRB (0.44) | THRBJAK1TYK2PDE2ANPC1 | |
| SCHEMBL1463387 | 0.89 | THRB (0.42) | THRBHCRTR1HCRTR2 | |
| SCHEMBL1463384 | 0.89 | THRB (0.42) | THRBHCRTR1HCRTR2 | |
| SCHEMBL1463388 | 0.89 | THRB (0.42) | THRBHCRTR1HCRTR2 | |
| SCHEMBL1463211 | 0.88 | HCRTR1 (0.45) | THRBALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL1463212 | 0.88 | HCRTR1 (0.45) | THRBALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL1463214 | 0.88 | HCRTR1 (0.45) | THRBALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL2702022 | 0.85 | JAK1 (0.44) | THRBJAK1TYK2HCRTR2F2 | |
| SCHEMBL1559805 | 0.82 | HCRTR2 (0.40) | THRBALDH1A1HSD17B10HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303871-B1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | claimed |
| US-7923470-B2 | Benzooxazoles as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | claimed |
| US-20100029664-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | US | claimed |
| US-8748430-B2 | Pyrrolidin-3yl-methylamine quinoxaline derivatives | Hoffmann-La Roche Inc (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748430-B2 | Pyrrolidin-3yl-methylamine quinoxaline derivatives | Hoffmann-La Roche Inc (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748430-B2 | Pyrrolidin-3yl-methylamine quinoxaline derivatives | Hoffmann-La Roche Inc (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120232084-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-13 | — | — | US | disclosed |
| US-20120232084-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-13 | — | — | US | disclosed |
| US-20120232084-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-13 | — | — | US | disclosed |
| US-8207220-B2 | Substituted benzothiazoles as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207220-B2 | Substituted benzothiazoles as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-7923470-B2 | Benzooxazoles as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | disclosed |
| EP-2303871-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20110071154-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | KNUST HENNER | 2011-03-24 | — | — | US | disclosed |
| US-20110071154-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | KNUST HENNER | 2011-03-24 | — | — | US | disclosed |
| US-20110071154-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | KNUST HENNER | 2011-03-24 | — | — | US | disclosed |
| WO-2010012620-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029664-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029664-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029664-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071154-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | THRB 412/4885JAK1 3727/4885TYK2 1596/4885 |
| US-20100029664-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | THRB 412/4885JAK1 3727/4885TYK2 1596/4885 |
| US-20120232084-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | THRB 412/4885JAK1 3727/4885TYK2 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.